Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Supplementary Table from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.

Bannoud N. et al, (2023), Proc Natl Acad Sci U S A, 120

Association between epigenetic heterogeneity of esophageal adenocarcinoma and response to first-line immunochemotherapy in LUD2015-005 Trial

Xie PF. et al, (2023), CANCER RESEARCH, 83

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Curigliano G. et al, (2023), Br J Cancer, 128

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Lee LYW. et al, (2022), JAMA Oncol

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.

Coupe N. et al, (2022), Cell Oncol (Dordr)

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Taylor CA. et al, (2022), Nat Med

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

Moreno V. et al, (2022), Cancer Immunol Immunother, 71, 2985 - 2998

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Curigliano G. et al, (2022), Br J Cancer

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Horgan D. et al, (2022), Healthcare (Basel), 10

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Larkin J. et al, (2022), Eur J Cancer, 173, 285 - 296

VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.

Cheng VWT. et al, (2022), Clin Cancer Res, 28, 2385 - 2396

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.

Garg M. et al, (2022), Nat Commun, 13

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.

Telli ML. et al, (2022), NPJ Breast Cancer, 8

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Long GV. et al, (2022), Ann Oncol, 33, 204 - 215

Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT.

Nwolise C. et al, (2021), Chronic Illn

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

Weber JS. et al, (2021), Eur J Cancer, 158, 225 - 233

Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.

Campbell NR. et al, (2021), Dev Cell, 56, 2808 - 2825.e10

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.

Watson RA. et al, (2021), Sci Immunol, 6

Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.

Sasson SC. et al, (2021), Gastroenterology, 161, 1229 - 1244.e9